Received 10 February 2009/Returned for modification 14 April 2009/Accepted 14 May 2009
|
|
- Michael Franklin
- 6 years ago
- Views:
Transcription
1 JOURNAL OF CLINICAL MICROBIOLOGY, July 2009, p Vol. 47, No /09/$ doi: /jcm Copyright 2009, American Society for Microbiology. All Rights Reserved. Development of a Disk Diffusion Method for Testing Moraxella catarrhalis Susceptibility Using Clinical and Laboratory Standards Institute Methods: a SENTRY Antimicrobial Surveillance Program Report Jan M. Bell, 1 John D. Turnidge, 1,2 * and Ronald N. Jones 3 Antimicrobial Research Laboratory, SA Pathology at the Women s and Children s Hospital, North Adelaide, 1 and the University of Adelaide, Adelaide, 2 South Australia 5006, and JMI Laboratories, North Liberty, Iowa Received 10 February 2009/Returned for modification 14 April 2009/Accepted 14 May 2009 Currently, there is no Clinical and Laboratory Standards Institute (CLSI) disk diffusion method for testing Moraxella catarrhalis susceptibility. We examined 318 clinical strains of M. catarrhalis obtained as part of the SENTRY (Asia-Pacific) Antimicrobial Surveillance Program, plus two ATCC strains. MICs were determined by the CLSI standard broth microdilution method, and zone diameters were determined on Mueller-Hinton agar incubated in 5% CO 2. All strains were examined for the presence of BRO-1 and BRO-2 -lactamases by using molecular techniques. Tentative zone diameter interpretive criteria were successfully developed for 19 antimicrobial agents, including nine -lactams, using current MIC interpretive criteria where available or wild-type cutoff values where no prior criteria were available. The proposed interpretive criteria were highly accurate, with <0.7% very major (falsely susceptible) and <1.0% major (falsely resistant) errors, respectively. Moraxella catarrhalis is a common commensal and occasionally pathogenic bacterium associated with a range of infections of the respiratory tract, including acute otitis media, acute sinusitis, and acute exacerbations of chronic bronchitis (5, 22, 34). Less commonly, this organism can cause more serious and invasive infection, including pneumonia, septicemia, and meningitis (4, 28). A number of standards-setting organizations, including the Société Française de Microbiologie (29) and the British Society for Antimicrobial Chemotherapy ( have developed disk diffusion tests and interpretive criteria for M. catarrhalis. Recently, the Clinical and Laboratory Standards Institute (CLSI) Subcommittee on Antimicrobial Susceptibility Testing published an interpretive guideline (6), but only for broth microdilution tests, using criteria essentially the same as those applied to Haemophilus spp. (10). Routine testing was not recommended by CLSI at the time of development of those guidelines. However, this species is frequently isolated from respiratory tract infection specimens and, when present in large numbers, can be assumed by the laboratory to be playing a pathogenic or copathogenic role and, therefore, can be reported to the clinician. For the many international laboratories using CLSI methods and standards, the lack of a disk diffusion method and interpretive criteria limits their ability to communicate useful information to the clinician for a common potential pathogen. We followed CLSI M23-A3 guidelines (7) for the development of a disk diffusion test for M. catarrhalis, supplemented with molecular tests for some resistance mechanisms to assist in the future enhancement of interpretive criteria. (This work was presented in part at the European Congress * Corresponding author. Mailing address: SA Pathology at the Women s and Children s Hospital, 72 King William Rd., North Adelaide, South Australia Phone: Fax: john.turnidge@health.sa.gov.au. Published ahead of print on 20 May of Clinical Microbiology and Infectious Diseases, Munich, Germany, 2007.) MATERIALS AND METHODS Isolates. Clinical strains of M. catarrhalis isolated from lower respiratory tract specimens and blood cultures were collected in 17 diagnostic laboratories in nine countries participating in the SENTRY Antimicrobial Surveillance Program from 1998 to 2004 (Asia-Pacific region) and referred to a monitoring laboratory in Adelaide, South Australia, for susceptibility testing (1). Strains were confirmed phenotypically to be M. catarrhalis by conventional carbohydrate fermentation reactions (23) and tributyrin hydrolysis (Remel, Lenexa, KS). Identifications were also confirmed using PCR according the method of Hendolin et al. (20, 21). M. catarrhalis ATCC ( -lactamase negative) and ATCC (BRO-2 -lactamase-positive 1908 strain) were used as control strains. Susceptibility testing. MICs to antimicrobials were determined using broth microdilution as described by CLSI (8) and custom-made panels (Trek Diagnostic Systems, East Grinstead, United Kingdom). Disk diffusion testing was performed as described by CLSI (9) on Mueller-Hinton agar and incubated for 20 to24hin5%co 2 by using CLSI disk strengths conventionally used for testing other species. Preliminary studies had suggested that a significant percentage of strains would not grow adequately on Mueller-Hinton agar (Bio-Rad, Mamesla-Coquette, France) in ambient air without the addition of CO 2. It was also shown that while added blood or lysed blood enhanced the growth of strains which grow poorly in ambient air, growth was most reliable when unsupplemented and incubated in CO 2. Zone diameters were read by the Osiris zone reader (Bio-Rad, Mames-la-Coquette, France), a system with proven reliability (26). All results were validated by visual inspection of the captured video image in the system and the system s zone diameter selection. Antimicrobials. The antimicrobials examined (MIC range and disk content tested) were benzylpenicillin (0.008 to 256 g/ml; 10 g), ampicillin (0.008 to 256 g/ml; 10 g), amoxicillin-clavulanate (0.008 to 1 g/ml; 20/10 g), ampicillinsulbactam (0.008 to 1 g/ml; 10/10 g), cephalexin (0.06 to 8 g/ml; 30 g), cefaclor (0.03 to 64 g/ml; 30 g), cefuroxime (0.25 to 16 g/ml; 30 g), ceftriaxone (0.002 to 16 g/ml; 30 g), meropenem (0.004 to 0.5 g/ml; 10 g), azithromycin (0.008 to 1 g/ml; 15 g), clarithromycin (0.008 to 1 g/ml; 15 g), erythromycin (0.03 to 4 g/ml; 15 g), ciprofloxacin (0.004 to 2 g/ml; 5 g), moxifloxacin (0.008 to 1 g/ml; 5 g), chloramphenicol (0.03 to 4 g/ml; 30 g), rifampin (0.008 to 1 g/ml; 5 g), gentamicin (0.016 to 1 g/ml; 10 g), tetracycline (0.03 to 64 g/ml; 30 g), and trimethoprim-sulfamethoxazole (0.06 to 4 g/ml; 1.25/23.76 g). Testing for -lactamase and tetracycline-resistant genes. All isolates were examined for -lactamase by using nitrocefin (Becton Dickinson, Sparks, MD). 2187
2 2188 BELL ET AL. J. CLIN. MICROBIOL. Agent TABLE 1. Estimated CO WT values This study (n 320) CO WT values ( g/ml) for strains used by c : Felmingham et al. (n 135) PCR testing for BRO -lactamase genes and tetracycline-resistant genes was as previously described (13, 16). Wild-type cutoff values. MIC distributions were analyzed and wild-type cutoff (CO WT ) MICs were calculated as previously described (32). Where a significant proportion of results were off scale, or where the number of wild-type strains was low, CO WT values were estimated by visual inspection. Results were compared to those available on the European Committee for Antimicrobial Susceptibility Testing (EUCAST) website ( and also to visual estimates of CO WT from previous studies which provided data on MIC distributions (2, 15, 24). Zone diameter interpretive criteria. Disk diffusion zone diameter interpretive criteria were developed as described by CLSI (7), using current CLSI MIC interpretative criteria (6, 8) where they were available and using CO WT values when they were not available or inappropriate. RESULTS Berk et al. (n 818) Karlowsky et al. (n 36) EUCAST (n variable) Penicillin 0.25 a b Ampicillin 0.06 a 0.06 b Amoxicillinclavulanate a b 0.03 b Ampicillinsulbactam 0.06 a Cephalexin 4 a Cefaclor 2 a 2 b Cefuroxime 1 a 2 b 1 4 Ceftriaxone a 0.25 b 0.06 b Meropenem a,b Erythromycin Clarithromycin Azithromycin Telithromycin 0.5 Tetracycline Rifampin Chloramphenicol Gentamicin Ciprofloxacin b Moxifloxacin a Visual estimate based on 20 -lactamase-negative strains. b Visual estimate due to predominantly off-scale results. c References for previous studies are as follows: Felmingham et al. (15), Berk et al. (2), Karlowsky et al. (24), and EUCAST ( /WT_EUCAST.htm). A total of 320 isolates of M. catarrhalis were tested, including 318 clinical strains and the two ATCC control strains. Of these, only 20 were -lactamase negative. A gene encoding a BRO enzyme was detected in all of the -lactamase-positive isolates. A total of 281 isolates were BRO-1, and 19 were BRO-2 (including one ATCC strain). Two strains had MICs to benzylpenicillin and ampicillin elevated above those of the wild type, suggesting the presence of either -lactamases other than those of the BRO type (14) or polymorphisms in BRO genes preventing PCR amplification. CO WT values. Because of the low numbers of -lactamasenegative (wild-type) isolates found (as expected from clinical practice), CO WT values could be estimated only visually for -lactams on the isolates from this study (Table 1). For the non- -lactams, it was possible to use statistical analysis to determine CO WT values (Table 1). MIC distributions. The MIC distributions for -lactams are shown in Table 2, and those for the non- -lactams are shown in Table 3. As expected, the presence of BRO-1 increased the MICs of benzylpenicillin and ampicillin substantially (Table 2). It also caused obvious but small increases in MICs for amoxicillin-clavulanate and ampicillin-sulbactam. BRO-1 also increased the MICs of all cephalosporins. For reasons that are unclear, the BRO-1 MIC distributions of benzylpenicillin, amoxicillin-clavulanate, cefaclor, and ceftriaxone appeared to be bimodal. The presence of BRO-2 had similar but lesspronounced effects on MIC distributions; for cephalexin and meropenem, it had no detectable effect. The BRO-2 MIC distribution for ceftriaxone was bimodal. Disk diffusion testing. Eighteen strains (5.6%) did not grow well or at all on Mueller-Hinton agar in 5% CO 2 and were excluded from the analyses of zone diameter interpretive criteria, as were four strains for which disk diffusion testing was not performed. All other strains grew well and showed confluent growth. Therefore, interpretive criteria were developed using the remaining 298 isolates. A notable feature of the strains that grew well was large zone diameters for strains with low MICs. These were attributed to the disk contents used, which are the conventional strengths used in CLSI disk diffusion testing. Selection of MIC interpretive criteria. Of the agents tested, the current CLSI M45-A guideline for infrequently isolated and fastidious bacteria (6) provides interpretive MIC breakpoints for M. catarrhalis for amoxicillin-clavulanate, cefaclor, cefuroxime, ceftriaxone, azithromycin, clarithromycin, erythromycin, ciprofloxacin, tetracycline, trimethoprim-sulfamethoxazole, chloramphenicol, and rifampin. These interpretive criteria have not been subjected to detailed pharmacodynamic or clinical analysis. They have been adopted from those currently used for Haemophilus species largely because M. catarrhalis is associated with a similar spectrum of diseases and has not undergone formal validation by the CLSI. Additional Haemophilus species MIC interpretative criteria were available in the CLSI M100-S18 (10) document for ampicillin-sulbactam, meropenem, and moxifloxacin. These were selected for zone diameter analysis. For two agents, penicillin and ampicillin, the respective CO WT values were each selected as a single MIC interpretive criterion, with the knowledge that these would be predictive of the presence of -lactamases. Similarly, CO WT values were selected as a single MIC interpretive criterion for the macrolides, because the intrinsic potency of this class is substantially greater against M. catarrhalis than it is against Haemophilus species, and therefore, the use of Haemophilus interpretive criteria would be misleading. Predicted resistance rates. Based on the selected MIC breakpoints (Table 4), nonsusceptibility rates of the 318 clinical isolates for the different antimicrobials were as follows: penicillin, 94.6%; ampicillin, 94.3%; amoxicillin-clavulanate, 0%; ampicillin-sulbactam, 0%; cefaclor, 24.8%; cefuroxime, 11.9%; ceftriaxone, 0.6%; meropenem, 0%; azithromycin, 0.3%; clarithromycin, 0.9%; erythromycin, 0.6%; ciprofloxacin, 0.3%; moxifloxacin, 0.3%; chloramphenicol, 0%; rifampin, 0%; gentamicin, 0%; tetracycline, 12.9%; and trimethoprim-sulfamethoxazole, 8.4%. All 41 tetracycline-nonsusceptible strains were categorized as resistant and contained the tet(b) gene. Almost all strains nonsusceptible to any of the agents tested, including non- -lactams, contained the BRO-1 -lactamase. The exceptions were two strains with MIC results for penicillin
3 VOL. 47, 2009 DISK METHOD FOR TESTING M. CATARRHALIS SUSCEPTIBILITY 2189 TABLE 2. MIC distributions for -lactams by -lactamase production Agent -Lactamase No. of strains for which MIC ( g/ml) a is: MIC mode ( g/ml) Penicillin Negative BRO BRO Ampicillin Negative BRO BRO Amoxicillin-clavulanate Negative BRO BRO Ampicillin-sulbactam Negative BRO BRO Cephalexin Negative BRO BRO Cefaclor Negative BRO BRO Cefuroxime Negative BRO BRO Ceftriaxone Negative BRO BRO Meropenem Negative BRO BRO a Solid, black vertical lines indicate COWT values, and hatched vertical bars indicate current CLSI breakpoints.
4 2190 BELL ET AL. J. CLIN. MICROBIOL. TABLE 3. MIC distributions for non- -lactams Agent No. of strains for which MIC ( g/ml) a is: MIC mode ( g/ml) Azithromycin Clarithromycin Erythromycin Ciprofloxacin Moxifloxacin Chloramphenicol ` 0.5 Rifampin Gentamicin Tetracycline TetB negative TetB positive Trimethoprim-sulfamethoxazole b a Solid, black vertical lines indicate CO WT values, and hatched vertical bars indicate current CLSI breakpoints. b CO WT and breakpoint are the same. and ampicillin elevated above the wild-type level, which contained neither BRO-1 nor BRO-2. Zone diameter interpretive criteria. Because the MIC interpretive criteria used (described above) have not been subjected to the full analysis required according to the CLSI M23-A3 guidelines (7), it was considered possible to set only tentative zone diameter interpretive criteria (Table 4). The requirements for establishing zone diameter interpretive criteria recommended in M23-A3 for unselected clinical strains, which is what our isolates represent, are simply that very major (falsely susceptible) discrepancy rates should be less than 1.5% and that major (falsely resistant) discrepancy rates should be less than 3%. No restriction is placed on minor discrepancy rates, although total error rates should be 10%. Using these criteria and the iterative methods described by Brunden et al. (3), we calculated the zone diameter interpretive criteria shown in Table 4. In addition, in the cases where there was a single MIC interpretive criterion, and Agent and disk content Source or reference TABLE 4. Proposed MIC and tentative zone diameter interpretive criteria Proposed zone diameter interpretive MIC interpretive criteria ( g/ml) % Intermediate; criteria (mm) % resistant e Susceptible Intermediate Resistant Susceptible Intermediate Resistant Discrepancy rates (%) Penicillin, 10 g This study a ; Ampicillin, 10 g Proposed in ; this study Amoxicillin-clavulanate, M45-A (6) 4/2 8/4 ; /10 g Ampicillin-sulbactam, M100-S18 2/1 4/2 ; /10 g (10) b Cefaclor, 30 g M45-A (6) ; Cefuroxime, 30 g M45-A (6) ; Ceftriaxone, 30 g M45-A (6) 2 ; Meropenem, 10 g M100-S ; (10) b Azithromycin, 15 g This study c ; Clarithromycin, 15 g This study c 0.5 ; Erythromycin, 15 g This study c 1 ; Ciprofloxacin, 5 g M45-A (6) 1 ; Moxifloxacin, 5 g M100-S18 1 ; (10) b Chloramphenicol, 30 g M45-A (6) d 2 ; Rifampin, 5 g M45-A (6) d 1 ; Gentamicin, 10 g This study c 0.5 ; Tetracycline, 30 g M45-A (6) ; Trimethoprimsulfamethoxazole, 1.25/23.75 g Very major M45-A (6) 0.5/9.5 1/19 2/38 4/76 6.0; a Principally to correlate with -lactamase results. b For Haemophilus influenzae. c For CO WT values used. d Modified as no resistance was detected, susceptible MIC was the only breakpoint used. e, not applicable. Major Minor
5 VOL. 47, 2009 DISK METHOD FOR TESTING M. CATARRHALIS SUSCEPTIBILITY 2191 FIG. 1. MIC zone diameter scattergrams for cefuroxime (A), erythromycin (B), and tetracycline (C). Solid horizontal lines represent MIC interpretive criteria. Dashed vertical lines represent calculated zone diameter interpretive criteria. where several zone diameter options yielded the same discrepancy rates (penicillin, ampicillin, amoxicillin-clavulanate, ampicillin-sulbactam, ceftriaxone, meropenem, ciprofloxacin, and moxifloxacin), we elected to set a conservative single zone diameter criterion at 1 millimeter less than the smallest zone diameter observed in the susceptible population. We also used a single zone diameter interpretive criterion using the same principle when no or only rare strains above wild-type level were detected (macrolides, chloramphenicol, rifampin, and gentamicin). The relatively poor activity of cephalexin against M catarrhalis, and its unusual distribution of MICs in the BRO-1-positive strains, precluded the setting of zone diameter criteria for this agent. Examples of the zone diameter MIC comparisons for cefuroxime, erythromycin, and tetracycline are shown in Fig. 1. DISCUSSION There has always been an occasional clinical need to test the susceptibility of M. catarrhalis. If the isolate comes from blood or another sterile body site culture (e.g., pleural fluid), treatment is clearly warranted. The organism is believed to be the third most common bacterium associated with acute exacerbations of chronic bronchitis and acute otitis media (4, 5, 14), both of which require antimicrobial treatment under certain circumstances. If resistance to commonly recommended agents
6 2192 BELL ET AL. J. CLIN. MICROBIOL. is emerging, then regular testing would also be warranted. The availability of disk diffusion methods and interpretive criteria for M. catarrhalis should go a large part of the way to providing guidance on reporting of pathogenic strains of the species for those laboratories unwilling or unable to conduct dilution testing. This is not the first attempt at developing a disk diffusion method like that of CLSI for M. catarrhalis. Doern and Tubert (12) used Mueller-Hinton agar that was both unsupplemented and supplemented with IsoVitalex and hemoglobin, incubated in air and 5 to 7% CO 2. Kibsey et al. (25) elected to use Mueller-Hinton agar incubated in 5% CO 2 for their disk diffusion study. They did not find strains with poor growth when agar was incubated in ambient air. Luman et al. (27) studied 231 isolates grown on Mueller-Hinton agar, using CLSI disk contents. Like our study, they too noted that a proportion of strains, 11% in their case, grew poorly in ambient air, and required retesting in 5% CO 2. Fung et al. (17) have also shown the feasibility of disk diffusion on media other than Mueller- Hinton agar. Treatment recommendations for infections caused by this species are largely based on clinical experience and not rigorous trials. The Sanford Guide (19) recommends amoxicillin-clavulanate or an expanded-spectrum or broad-spectrum oral cephalosporin as primary choices, with alternatives being azithromycin, clarithromycin, dirithromycin, and telithromycin. The Sanford Guide states that erythromycin, doxycycline, and fluoroquinolones are known to be effective. Meza et al. (30) recommend -lactamase-stable cephalosporins or amoxicillin-clavulanate as the first line but provide information on a broad range of other agents, including trimethoprim-sulfamethoxazole, macrolides, fluoroquinolones, doxycycline, and chloramphenicol, for a number of infections, ranging from mild to serious. These recommendations drove our choice of agents to examine. We appreciate that the validity of many of the MIC interpretive criteria for M. catarrhalis is preliminary and unconfirmed. For the determination of breakpoints for an antimicrobial against a pathogen or group of pathogens, ideally reliable data are required from studies of the in vitro activity, the pharmacodynamics of the antimicrobial, and the in vivo efficacy rates from prospective clinical outcome studies (33). Unfortunately, reliable clinical outcome data on effective antimicrobial agents are scarce and are insufficient to draw conclusions about eradication rates. Furthermore, target pharmacokinetic/pharmacodynamic values for macrolides, tetracyclines, rifampin, aminoglycosides, or folate antagonists have not been uniformly accepted, As a consequence, we have selected MIC interpretive criteria mostly from Haemophilus influenzae, given the similarity of its clinical conditions to those of Haemophilus spp. in which M. catarrhalis is found. However, we believe the use of Haemophilus-derived breakpoints for the macrolides is inappropriate because the intrinsic activity of macrolides is substantially greater against Moraxella. Instead, we elected to use the CO WT values found in this study for this class of agents. Acquired resistance mechanisms to macrolides have yet to be convincingly demonstrated in M. catarrhalis, even though occasional strains with elevated MICs are detected in large surveillance program studies (2). Indeed, previous work by one of us has suggested that macrolide resistance is more likely to represent misidentification of commensal Neisseria species as M. catarrhalis (31). M. catarrhalis isolates frequently harbor -lactamases, almost always of the BRO type. However, -lactamase production is not a characteristic of the wild type, as early studies showed that M. catarrhalis was always -lactamase negative until as recently as 1975 (35). Subsequent studies have shown a steady evolution to more than 80 to 90% of all clinical isolates worldwide being -lactamase producers (34). The rate of -lactamase production in our clinical strains, which came from eight countries in the Asia-Pacific region, was even higher, at 302/318 or 94.3%. We confirmed that BRO-1 had higher activity than did BRO-2, which was previously noted in other studies including strains from other regions in the SENTRY program (11, 35). Ours is one of the few studies to examine the effect of this difference on the MIC distributions of -lactams in a broad population of clinical isolates. Fung et al. (18) showed significant differences between the geometric mean MICs of BRO-1- and BRO-2-producing strains for ampicillin, and they showed smaller differences for amoxicillinclavulanate, loracarbef, cefixime, and cefetamet. Deshpande et al. (11), looking at SENTRY program isolates worldwide, showed a difference in the MIC distributions of penicillin and ampicillin between 385 BRO-1-positive isolates and 14 BRO- 2-positive isolates. We also demonstrated a substantial upward shift in the MICs of BRO-1- and BRO-2-containing isolates for penicillin and ampicillin. However, we also noted a smaller but still significant upward shift in amoxicillin-clavulanate and, to a lesser extent, ampicillin-sulbactam, due to these enzymes. The same was true for cefaclor, cefuroxime, and ceftriaxone, but not for cephalexin, which appears relatively stable to BRO -lactamases based on standard MIC measurement. For this reason, a small to moderate proportion of the -lactamaseproducing population were categorized as nonsusceptible to cefaclor, cefuroxime, and ceftriaxone. This nonsusceptibility was driven by the choice of MIC breakpoints found in CLSI guideline M45A (6), which in turn originated from those for Haemophilus spp. (10). Apart from resistance mediated by -lactamases, resistance to other classes is relatively uncommon. The only resistances that featured in our region were those for tetracycline (12.8%) and trimethoprim-sulfamethoxazole (2.5%). The few strains that were categorized as nonsusceptible to macrolides had MIC results that were one twofold dilution higher than the calculated cutoff values and are unlikely to harbor true resistance mechanisms. Of most interest were the considerable rates of nonsusceptibility and resistance to the oral broadspectrum cephalosporins (cefaclor and cefuroxime) using the current breakpoints (derived from H. influenzae). These rates suggest that the choice of these agents as empirical therapy may be inadvisable. There are some potential limitations of our findings. We used a single batch of Mueller-Hinton agar. Although there is not a CLSI requirement to use more than one lot or manufacturer of Mueller-Hinton agar for disk diffusion studies, it is possible that differences may exist between lots and manufacturers, especially for antimicrobials affected by divalent cations. We did not pursue the molecular mechanisms of resistance that might explain resistance to tri-
7 VOL. 47, 2009 DISK METHOD FOR TESTING M. CATARRHALIS SUSCEPTIBILITY 2193 methoprim-sulfamethoxazole, although this would benefit from further study. In summary, we have developed tentative zone diameter interpretive criteria for a range of antimicrobials that might be considered for the treatment of M. catarrhalis infections when required. We expect that future work will result in modifications to these criteria, especially as pharmacokinetic/pharmacodynamic targets become fully developed for all drug classes and as clinical outcome studies provide more information on the efficacy of eradication. ACKNOWLEDGMENTS This study was funded in part by the 20th International Congress of Chemotherapy Research Institute. We are very grateful to Bio-Rad Australia for the kind donation of the Osiris zone reader. REFERENCES 1. Bell, J. M., J. D. Turnidge, M. A. Pfaller, and R. N. Jones In vitro assessment of gatifloxacin spectrum and potency tested against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae isolates from the Asia-Western Pacific component of the SENTRY antimicrobial surveillance program ( ). Diagn. Microbiol. Infect. Dis. 43: Berk, S. L., J. H. Kalbfleisch, et al Antibiotic susceptibility patterns of community-acquired respiratory isolates of Moraxella catarrhalis in western Europe and in the USA. J. Antimicrob. Chemother. 38(Suppl. A): Brunden, M. N., G. E. Zurenko, and B. Kapik Modification of the error-rate bounded classification scheme for use with two MIC break points. Diagn. Microbiol. Infect. Dis. 15: Catlin, B. W Branhamella catarrhalis: an organism gaining respect as a pathogen. Clin. Microbiol. Rev. 3: Christensen, J. J Moraxella (Branhamella) catarrhalis: clinical, microbiological and immunological features in lower respiratory tract infections. APMIS 88: Clinical and Laboratory Standards Institute Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria. Approved guideline M45-A. CLSI, Wayne, PA. 7. Clinical and Laboratory Standards Institute Development of in vitro susceptibility testing criteria and quality control parameters. Approved guideline M23-A3. CLSI, Wayne, PA. 8. Clinical and Laboratory Standards Institute Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved guideline M7-A8. CLSI, Wayne, PA. 9. Clinical and Laboratory Standards Institute Performance standard for antimicrobial disk susceptibility tests. M2-A10. CLSI, Wayne, PA. 10. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing; 19th informational supplement. M100-S18. CLSI, Wayne, PA. 11. Deshpande, L. M., H. S. Sader, T. R. Fritsche, and R. N. Jones Contemporary prevalence of BRO -lactamases in Moraxella catarrhalis: report from the SENTRY antimicrobial surveillance program (North America, 1997 to 2004). J. Clin. Microbiol. 44: Doern, G. V., and T. Tubert Disk diffusion susceptibility testing of Branhemella catarrhalis with ampicillin and seven other antimicrobial agents. Antimicrob. Agents and Chemother. 31: du Plessis, M Rapid discrimination between BRO -lactamases from clinical isolates of Moraxella catarrhalis using restriction endonuclease analysis. Diagn. Microbiol. Infect. Dis. 39: Enright, M. C., and H. McKenzie Moraxella (Branhamella) catarrhalis clinical and molecular aspects of a rediscovered pathogen. J. Med. Microbiol. 46: Felmingham, D., R. N. Grüneberg, et al A multicentre collaborative study of the antimicrobial susceptibility of community-acquired, lower respiratory tract pathogens : the Alexander Project. J. Antimicrob. Chemother. 38(Suppl. A): Fluit, A. C., A. Florijn, J. Verhoef, and D. Milatovic Presence of tetracycline resistance determinants and susceptibility to tigecycline and minocycline. Antimicrob. Agents Chemother. 49: Fung, C. P., M. Powell, A. Seymour, M. Yuan, and J. D. Williams The antimicrobial susceptibility of Moraxella catarrhalis isolated in England and Scotland in J. Antimicrob. Chemother. 30: Fung, C. P., S.-F. Yeo, and D. M. Livermore Susceptibility of Moraxella catarrhalis isolates to -lactam antibiotic in relation to -lactamase patterns. J. Antimicrob. Chemother. 33: Gilbert, D. N., R. C. Moellering, G. M. Eliopoulos, and M. A. Sande (ed.) The Sanford guide to antimicrobial therapy, 38th ed. Antimicrobial Therapy, Inc., Sperryville, VA. 20. Hendolin, P. H., A. Markkanen, J. Ylikoski, and J. J. Wahlfors Use of multiplex PCR for simultaneous detection of four bacterial species in middle ear effusions. J. Clin. Microbiol. 35: Hendolin, P. H., I. Paulin, and J. Ylikoski Clinically applicable multiplex PCR for four middle ear pathogens. J. Clin. Microbiol. 38: Ioannidis, J. P. A., M. Worthington, J. K. Griffiths, and D. R. Snydman Spectrum and significance of bacteremia due to Moraxella catarrhalis. Clin. Infect. Dis. 21: Janda, W. M., and J. S. Knapp Neisseria and Moraxella catarrhalis, p In P. R. Murray, E. J. Baron, J. H. Jorgensen, M. A. Pfaller, and R. H. Yolken (ed.), Manual of clinical microbiology, 8th ed. ASM Press, Washington, DC. 24. Karlowsky, J. A., I. A. Critchley, D. C. Draghi, M. E. Jones, C. Thornsberry, and D. F. Sahm Activity of cefditoren against -lactamase-positive and -negative Haemophilus influenzae and Moraxella catarrhalis. Diagn. Microbiol. Infect. Dis. 42: Kibsey, P. C., R. P. Rennie, and J. E. Rushton Disk diffusion versus broth microdilution susceptibility testing of Haemophilus species and Moraxella catarrhalis using seven oral antimicrobial agents: application of updated susceptibility guidelines of the National Committee for Clinical Laboratory Standards. J. Clin. Microbiol. 32: Kolbert, M., F. Chegrani, and P. M. Shah Evaluation of the OSIRIS video reader as an automated measurement system for the agar disk diffusion technique. Clin. Microbiol. Infect. 10: Luman, I., R. W. Wilson, R. J. Wallace, and D. R. Nash Disk diffusion susceptibility testing of Branhamella catarrhalis and relationship between -lactam zone size to -lactamase production. Antimicrob. Agents Chemother. 30: McGregor, K., B. J. Chang, B. Mee, and T. V. Riley Moraxella catarrhalis: clinical significance, antimicrobial susceptibility and BRO betalactamases. Eur. J. Clin. Microbiol. Infect. Dis. 17: Members of the SFM Antibiogram Committee Comité de l Antibiogramme de la Société Française de Microbiologie Report Int. J. Antimicrob. Agents 21: Meza, A., A. Verghese, and S. L. Berk Moraxella catarrhalis, p In V. L. Yu, R. Weber, and D. Raoult (ed.), Antimicrobial therapy and vaccines, vol. 1. Apple Tree Productions, New York, NY. 31. Singh, S., K. M. Cisera, J. D. Turnidge, and E. G. Russell Selection of optimum laboratory tests for the identification of Moraxella catarrhalis. Pathology 29: Turnidge, J., G. Kalhmeter, and G. Kronvall Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values. Clin. Microbiol. Infect. 12: Turnidge, J., and D. L. Paterson Setting and revising antibacterial susceptibility breakpoints. Clin. Microbiol. Rev. 20: Verduin, C. M., C. Hol, H. van Dijk, and A. van Belkum Moraxella catarrhalis: from emerging to established pathogen. Clin. Microbiol. Rev. 15: Wallace, R. J., W. A. Steingrube, D. R. Nash, D. G. Hollis, C. Flanagan, B. A. Brown, A. Labidi, and R. E. Weaver BRO -lactamases of Branhamella catarrhalis and Moraxella subgenus Moraxella, including evidence for chromosomal -lactamase transfer by conjugation in B. catarrhalis, M. nonliquefaciens, and M. lacunata. Antimicrob. Agents Chemother. 33:
ORIGINAL ARTICLE. Focus Technologies, Inc., 1 Hilversum, The Netherlands, 2 Herndon, Virginia and 3 Franklin, Tennessee, USA
ORIGINAL ARTICLE In vitro susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: a European multicenter study during 2000 2001 M. E. Jones 1, R. S. Blosser-Middleton
More informationa. 379 laboratories provided quantitative results, e.g (DD method) to 35.4% (MIC method) of all participants; see Table 2.
AND QUANTITATIVE PRECISION (SAMPLE UR-01, 2017) Background and Plan of Analysis Sample UR-01 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control as recommended by EUCAST Version 5.0, valid from 015-01-09 This document should be cited as "The
More informationWhat s new in EUCAST methods?
What s new in EUCAST methods? Derek Brown EUCAST Scientific Secretary Interactive question 1 MIC determination MH-F broth for broth microdilution testing of fastidious microorganisms Gradient MIC tests
More informationEUCAST recommended strains for internal quality control
EUCAST recommended strains for internal quality control Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus influenzae ATCC 59 ATCC
More informationEvaluation of a computerized antimicrobial susceptibility system with bacteria isolated from animals
J Vet Diagn Invest :164 168 (1998) Evaluation of a computerized antimicrobial susceptibility system with bacteria isolated from animals Susannah K. Hubert, Phouc Dinh Nguyen, Robert D. Walker Abstract.
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control for MIC determination and disk diffusion as recommended by EUCAST Version 8.0, valid from 018-01-01
More informationJanuary 2014 Vol. 34 No. 1
January 2014 Vol. 34 No. 1. and Minimum Inhibitory Concentration (MIC) Interpretive Standards for Testing Conditions Medium: diffusion: Mueller-Hinton agar (MHA) Broth dilution: cation-adjusted Mueller-Hinton
More informationNational Clinical Guideline Centre Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults
National Clinical Guideline Centre Antibiotic classifications Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults Clinical guideline 191 Appendix N 3 December 2014
More information56 Clinical and Laboratory Standards Institute. All rights reserved.
Table 2C 56 Clinical and Laboratory Standards Institute. All rights reserved. Table 2C. Zone Diameter and Minimal Inhibitory Concentration Breakpoints for Testing Conditions Medium: Inoculum: diffusion:
More informationand Health Sciences, Wayne State University and Detroit Receiving Hospital, Detroit, MI, USA
Journal of Antimicrobial Chemotherapy (2004) 54, Suppl. S1, i7 i15 DOI: 10.1093/jac/dkh313 JAC Antimicrobial susceptibility of Streptococcus pneumoniae, Streptococcus pyogenes and Haemophilus influenzae
More informationSuggestions for appropriate agents to include in routine antimicrobial susceptibility testing
Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing These suggestions are intended to indicate minimum sets of agents to test routinely in a diagnostic laboratory
More informationJanuary 2014 Vol. 34 No. 1
January 2014 Vol. 34 No. 1. and Minimal Inhibitory Concentration (MIC) Interpretive Standards for Testing Conditions Medium: diffusion: Mueller-Hinton agar (MHA) roth dilution: cation-adjusted Mueller-Hinton
More informationRoutine internal quality control as recommended by EUCAST Version 3.1, valid from
Routine internal quality control as recommended by EUCAST Version.1, valid from 01-01-01 Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus
More informationHelp with moving disc diffusion methods from BSAC to EUCAST. Media BSAC EUCAST
Help with moving disc diffusion methods from BSAC to EUCAST This document sets out the main differences between the BSAC and EUCAST disc diffusion methods with specific emphasis on preparation prior to
More informationResistance Among Streptococcus pneumoniae: Patterns, Mechanisms, Interpreting the Breakpoints
...PRESENTATIONS... Resistance Among Streptococcus pneumoniae: Patterns, Mechanisms, Interpreting the Breakpoints Angela B. Brueggemann, MS; and Gary V. Doern, PhD Presentation Summary Streptococcus pneumoniae
More informationEDUCATIONAL COMMENTARY - Methicillin-Resistant Staphylococcus aureus: An Update
EDUCATIONAL COMMENTARY - Methicillin-Resistant Staphylococcus aureus: An Update Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain
More informationMicrobiology, Southmead Hospital, Southmead Road, Bristol BS10 5NB, UK
Journal of Antimicrobial Chemotherapy (2008) 62, Suppl. 2, ii97 ii103 doi:10.1093/jac/dkn356 Non-susceptibility trends among Haemophilus influenzae and Moraxella catarrhalis from community-acquired respiratory
More informationBackground and Plan of Analysis
ENTEROCOCCI Background and Plan of Analysis UR-11 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony count, to perform the identification
More informationStreptococcus pneumoniae. Oxacillin 1 µg as screen for beta-lactam resistance
Streptococcus pneumoniae Oxacillin µg as screen for beta-lactam resistance Version 6. June Streptococcus pneumoniae and zone diameter correlates The following histograms present inhibition zone diameter
More informationIntrinsic, implied and default resistance
Appendix A Intrinsic, implied and default resistance Magiorakos et al. [1] and CLSI [2] are our primary sources of information on intrinsic resistance. Sanford et al. [3] and Gilbert et al. [4] have been
More informationSUPPLEMENT ARTICLE. among clinical isolates of S. pneumoniae in the United
SUPPLEMENT ARTICLE Regional Trends in Antimicrobial Resistance among Clinical Isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: Results from
More informationPlease distribute a copy of this information to each provider in your organization.
HEALTH ADVISORY TO: Physicians and other Healthcare Providers Please distribute a copy of this information to each provider in your organization. Questions regarding this information may be directed to
More informationجداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی
جداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی ویرایش دوم بر اساس ed., 2017 CLSI M100 27 th تابستان ۶۹۳۱ تهیه
More informationAntimicrobial Pharmacodynamics
Antimicrobial Pharmacodynamics November 28, 2007 George P. Allen, Pharm.D. Assistant Professor, Pharmacy Practice OSU College of Pharmacy at OHSU Objectives Become familiar with PD parameters what they
More informationThe Basics: Using CLSI Antimicrobial Susceptibility Testing Standards
The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards Janet A. Hindler, MCLS, MT(ASCP) UCLA Health System Los Angeles, California, USA jhindler@ucla.edu 1 Learning Objectives Describe information
More informationORIGINAL ARTICLE. influenzae and Moraxella catarrhalis to antimicrobial agents used to treat respiratory tract infections.
ORIGINAL ARTICLE Antimicrobial susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis collected from five centers in Brazil, 1997 98 I. A. Critchley 1, C. Thornsberry
More informationDisk Diffusion Susceptibility Testing of Branhamella catarrhalis
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Oct. 1987, p. 1519-1523 Vol. 31, No. 10 0066-4804/87/101519-05$00/0 Copyright 1987, American Society for Microbiology Disk Diffusion Susceptibility Testing of Branhamella
More informationTel: Fax:
CONCISE COMMUNICATION Bactericidal activity and synergy studies of BAL,a novel pyrrolidinone--ylidenemethyl cephem,tested against streptococci, enterococci and methicillin-resistant staphylococci L. M.
More informationEUCAST-and CLSI potency NEO-SENSITABS
EUCASTand CLSI potency NEOSENSITABS Neo Sensitabs Page 1 / 6 Document: 6.2.0 Fastidious organisms EUCAST Interpretation zones and MIC breakpoints according to recommendations by the "Comité de l'antibiogramme
More informationEducating Clinical and Public Health Laboratories About Antimicrobial Resistance Challenges
Educating Clinical and Public Health Laboratories About Antimicrobial Resistance Challenges Janet Hindler, MCLS MT(ASCP) UCLA Medical Center jhindler@ucla.edu also working as a consultant with the Association
More informationAntibiotic Reference Laboratory, Institute of Environmental Science and Research Limited (ESR); August 2017
Antimicrobial susceptibility of Shigella, 2015 and 2016 Helen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory, Institute of Environmental Science and Research Limited (ESR); August 2017
More informationPrinciples and Practice of Antimicrobial Susceptibility Testing. Microbiology Technical Workshop 25 th September 2013
Principles and Practice of Antimicrobial Susceptibility Testing Microbiology Technical Workshop 25 th September 2013 Scope History Why Perform Antimicrobial Susceptibility Testing? How to Perform an Antimicrobial
More informationPerformance Information. Vet use only
Performance Information Vet use only Performance of plates read manually was measured in three sites. Each centre tested Enterobacteriaceae, streptococci, staphylococci and pseudomonas-like organisms.
More informationESBL Producers An Increasing Problem: An Overview Of An Underrated Threat
ESBL Producers An Increasing Problem: An Overview Of An Underrated Threat Hicham Ezzat Professor of Microbiology and Immunology Cairo University Introduction 1 Since the 1980s there have been dramatic
More informationANTIMICROBIAL SUSCEPTIBILITY DETECTION OF ELEVATED MICs TO PENICILLINS IN β- HAEMOLYTIC STREPTOCOCCI
HAEMOLYTIC STREPTOCOCCI This specimen was designated as a sample from a skin wound that was to be cultured, identified to species level and susceptibility tested [1-3]. The culture contained a Streptococcus
More informationAnnual Report: Table 1. Antimicrobial Susceptibility Results for 2,488 Isolates of S. pneumoniae Collected Nationally, 2005 MIC (µg/ml)
Streptococcus pneumoniae Annual Report: 5 In 5, a total of, isolates of pneumococci were collected from 59 clinical microbiology laboratories across Canada. Of these, 733 (9.5%) were isolated from blood
More informationCompliance of manufacturers of AST materials and devices with EUCAST guidelines
Compliance of manufacturers of AST materials and devices with EUCAST guidelines Data are based on questionnaires to manufacturers of materials and devices for antimicrobial susceptibility testing. The
More informationAPPENDIX III - DOUBLE DISK TEST FOR ESBL
Policy # MI\ANTI\04\03\v03 Page 1 of 5 Section: Antimicrobial Susceptibility Testing Manual Subject Title: Appendix III - Double Disk Test for ESBL Issued by: LABORATORY MANAGER Original Date: January
More informationTreatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani
Treatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani 30-1-2018 1 Objectives of the lecture At the end of lecture, the students should be able to understand the following:
More informationEUCAST Workshop: Antimicrobial susceptibility testing with EUCAST breakpoints and methods
EUCAST Workshop: Antimicrobial susceptibility testing with EUCAST breakpoints and methods Susceptibility testing of infrequently isolated fastidious organisms Luis Martinez-Martínez Service of Microbiology
More informationAntibiotics in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Antibiotics in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease Sung Kyu Kim, M.D.Young Sam Kim, M.D. Department of Internal Medicine Yonsei University College of Medicine,
More informationThere are two international organisations that set up guidelines and interpretive breakpoints for bacteriology and susceptibility
ANTIMICROBIAL SUSCEPTIBILITY TESTING ON MILK SAMPLES Method and guidelines There are two international organisations that set up guidelines and interpretive breakpoints for bacteriology and susceptibility
More informationMarc Decramer 3. Respiratory Division, University Hospitals Leuven, Leuven, Belgium
AAC Accepts, published online ahead of print on April 0 Antimicrob. Agents Chemother. doi:./aac.0001- Copyright 0, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
More informationSAMPLE. Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated From Animals
VET01 5th Edition Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated From Animals This standard covers the current recommended methods for disk diffusion
More informationPractical approach to Antimicrobial susceptibility testing (AST) and quality control
Practical approach to Antimicrobial susceptibility testing (AST) and quality control A/Professor John Ferguson, Microbiologist & Infectious Diseases Physician, Pathology North, University of Newcastle,
More informationESCMID Online Lecture Library. by author
Quality Assurance of antimicrobial susceptibility testing Derek Brown EUCAST Scientific Secretary ESCMID Postgraduate Education Course, Linz, 17 September 2014 Quality Assurance The total process by which
More informationVersion 1.01 (01/10/2016)
CHN58: ANTIMICROBIAL SUSCEPTIBILITY TESTING (CLSI) 1.0 PURPOSE / INTRODUCTION: 1.1 Introduction Antimicrobial susceptibility tests are performed in order to determine whether a pathogen is likely to be
More informationShould we test Clostridium difficile for antimicrobial resistance? by author
Should we test Clostridium difficile for antimicrobial resistance? Paola Mastrantonio Department of Infectious Diseases Istituto Superiore di Sanità, Rome,Italy Clostridium difficile infection (CDI) (first
More informationAntimicrobial Susceptibility Testing: The Basics
Antimicrobial Susceptibility Testing: The Basics Susan E. Sharp, Ph.D., DABMM, FAAM Director, Airport Way Regional Laboratory Director, Regional Microbiology and Molecular Infectious Diseases Laboratories
More informationConcise Antibiogram Toolkit Background
Background This toolkit is designed to guide nursing homes in creating their own antibiograms, an important tool for guiding empiric antimicrobial therapy. Information about antibiograms and instructions
More information21 st Expert Committee on Selection and Use of Essential Medicines Peer Review Report Antibiotics Review
(1) Have all important studies/evidence of which you are aware been included in the application? Yes No Please provide brief comments on any relevant studies that have not been included: (2) For each of
More informationWhat is new in 2011: Methods and breakpoints in relation to subcommittees and expert groups. by author. Gunnar Kahlmeter, Derek Brown
What is new in 2011: Methods and breakpoints in relation to subcommittees and expert groups Gunnar Kahlmeter, Derek Brown Izmir, February 2011 Anaerobes subcommittee EUCAST Subcommittee on breakpoints
More informationChildrens Hospital Antibiogram for 2012 (Based on data from 2011)
Childrens Hospital Antibiogram for 2012 (Based on data from 2011) Prepared by: Department of Clinical Microbiology, Health Sciences Centre For further information contact: Andrew Walkty, MD, FRCPC Medical
More informationQuality assurance of antimicrobial susceptibility testing
Quality assurance of antimicrobial susceptibility testing Derek Brown Routine quality control Repeated testing of controls in parallel with tests to ensure that the test system is performing reproducibly
More informationDefining Resistance and Susceptibility: What S, I, and R Mean to You
Defining Resistance and Susceptibility: What S, I, and R Mean to You Michael D. Apley, DVM, PhD, DACVCP Department of Clinical Sciences College of Veterinary Medicine Kansas State University Susceptible
More informationJasmine M. Chaitram, 1,2 * Laura A. Jevitt, 1,2 Sara Lary, 1,2 Fred C. Tenover, 1,2 and The WHO Antimicrobial Resistance Group 3,4
JOURNAL OF CLINICAL MICROBIOLOGY, June 2003, p. 2372 2377 Vol. 41, No. 6 0095-1137/03/$08.00 0 DOI: 10.1128/JCM.41.6.2372 2377.2003 The World Health Organization s External Quality Assurance System Proficiency
More informationESCMID Online Lecture Library. by author
Expert rules in susceptibility testing EUCAST-ESGARS-EPASG Educational Workshop Linz, 16 19 September, 2014 Dr. Rafael Cantón Hospital Universitario Ramón y Cajal SERVICIO DE MICROBIOLOGÍA Y PARASITOLOGÍA
More informationAntibiotics in vitro : Which properties do we need to consider for optimizing our therapeutic choice?
Antibiotics in vitro : Which properties do we need to consider for optimizing our therapeutic choice? With the support of Wallonie-Bruxelles-International 1-1 In vitro evaluation of antibiotics : the antibiogram
More informationAntimicrobial susceptibility of Salmonella, 2016
susceptibility of Salmonella, 06 Hospital and community laboratories are requested to refer all Salmonella isolated from human salmonellosis cases to ESR for serotyping and the laboratory-based surveillance
More informationMICRONAUT MICRONAUT-S Detection of Resistance Mechanisms. Innovation with Integrity BMD MIC
MICRONAUT Detection of Resistance Mechanisms Innovation with Integrity BMD MIC Automated and Customized Susceptibility Testing For detection of resistance mechanisms and specific resistances of clinical
More informationUnderstanding the Hospital Antibiogram
Understanding the Hospital Antibiogram Sharon Erdman, PharmD Clinical Professor Purdue University College of Pharmacy Infectious Diseases Clinical Pharmacist Eskenazi Health 5 Understanding the Hospital
More informationIn Vitro Antimicrobial Activity of CP-99,219, a Novel Azabicyclo-Naphthyridone
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 993, p. 39-353 0066-0/93/0039-05$0.00/0 Copyright 993, American Society for Microbiology Vol. 37, No. In Vitro Antimicrobial Activity of, a Novel Azabicyclo-Naphthyridone
More informationEXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING
EXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING CHN61: EXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING 1.1 Introduction A common mechanism of bacterial resistance to beta-lactam antibiotics is the production
More informationReceived: February 29, 2008 Revised: July 22, 2008 Accepted: August 4, 2008
J Microbiol Immunol Infect. 29;42:317-323 In vitro susceptibilities of aerobic and facultative anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections at a medical center
More informationBacterial Resistance of Respiratory Pathogens. John C. Rotschafer, Pharm.D. University of Minnesota
Bacterial Resistance of Respiratory Pathogens John C. Rotschafer, Pharm.D. University of Minnesota Antibiotic Misuse ~150 million courses of antibiotic prescribed by office based prescribers Estimated
More informationMINIREVIEW Antimicrobial Susceptibility Testing of Haemophilus influenzae, Branhamella catarrhalis, and Neisseria gonorrhoeae
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Dec. 1988, P. 1747-1753 0066-4804/88/121747-07$02.00/0 Copyright C 1988, American Society for Microbiology Vol. 32, No. 12 MINIREVIEW Antimicrobial Susceptibility
More information2016 Antibiotic Susceptibility Report
Fairview Northland Medical Center and Elk River, Milaca, Princeton and Zimmerman Clinics 2016 Antibiotic Susceptibility Report GRAM-NEGATIVE ORGANISMS 2016 Gram-Negative Non-Urine The number of isolates
More informationTHE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS
THE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS Stefanie Desmet University Hospitals Leuven Laboratory medicine microbiology stefanie.desmet@uzleuven.be
More informationKeywords: amoxicillin/clavulanate, respiratory tract infection, antimicrobial resistance, pharmacokinetics/pharmacodynamics, appropriate prescribing
Journal of Antimicrobial Chemotherapy (2004) 53, Suppl. S1, i3 i20 DOI: 10.1093/jac/dkh050 Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review
More informationCompliance of manufacturers of AST materials and devices with EUCAST guidelines
Compliance of manufacturers of AST materials and devices with EUCAST guidelines Data are based on questionnaires to manufacturers of materials and devices for antimicrobial susceptibility testing. The
More informationAntimicrobial Stewardship Strategy: Antibiograms
Antimicrobial Stewardship Strategy: Antibiograms A summary of the cumulative susceptibility of bacterial isolates to formulary antibiotics in a given institution or region. Its main functions are to guide
More informationMethod Preferences and Test Accuracy of Antimicrobial Susceptibility Testing
Method Preferences and Test Accuracy of Antimicrobial Susceptibility Testing Updates From the College of American Pathologists Microbiology Surveys Program (2000) Ronald N. Jones, MD; for the College of
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #65 (NQF 0069): Appropriate Treatment for Children with Upper Respiratory Infection (URI) National Quality Strategy Domain: Efficiency and Cost Reduction 2018 OPTIONS FOR INDIVIDUAL MEASURES:
More informationActivity of Linezolid Tested Against Uncommonly Isolated Gram-positive ACCEPTED
AAC Accepts, published online ahead of print on 8 January 2007 Antimicrob. Agents Chemother. doi:10.1128/aac.01496-06 Copyright 2007, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationOver 40 Posters/Abstracts in Support of TREK Presented at the 2004 ECCMID
Over 40 Posters/Abstracts in Support of TREK Presented at the ECCMID This was our best ECCMID ever for TREK presentations! The following posters and abstracts were in support of TREK products! Sensititre
More informationPROTOCOL for serotyping and antimicrobial susceptibility testing of Salmonella test strains
PROTOCOL for serotyping and antimicrobial susceptibility testing of Salmonella test strains 1 INTRODUCTION... 1 2 OBJECTIVES... 2 3 OUTLINE OF THE EQAS 2017... 2 3.1 Shipping, receipt and storage of strains...
More informationLevofloxacin and moxifloxacin resistant Haemophilus influenzae in a patient with common variable immunodeficiency (CVID): a case report
46 Case Report Levofloxacin and moxifloxacin resistant Haemophilus influenzae in a patient with common variable immunodeficiency (CVID): a case report CT Hapuarachchi 1, GK Karunaratne 2, NR de Silva 3,
More informationPrevalence of Metallo-Beta-Lactamase Producing Pseudomonas aeruginosa and its antibiogram in a tertiary care centre
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 4 Number 9 (2015) pp. 952-956 http://www.ijcmas.com Original Research Article Prevalence of Metallo-Beta-Lactamase
More informationOriginal Article. Ratri Hortiwakul, M.Sc.*, Pantip Chayakul, M.D.*, Natnicha Ingviya, B.Sc.**
Original Article In Vitro Activity of Cefminox and Other β-lactam Antibiotics Against Clinical Isolates of Extended- Spectrum-β-lactamase-Producing Klebsiella pneumoniae and Escherichia coli Ratri Hortiwakul,
More informationQuality ID #66: Appropriate Testing for Children with Pharyngitis National Quality Strategy Domain: Efficiency and Cost Reduction
Quality ID #66: Appropriate Testing for Children with Pharyngitis National Quality Strategy Domain: Efficiency and Cost Reduction 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process
More informationEvaluation of MicroScan MIC Panels for Detection of
JOURNAL OF CLINICAL MICROBIOLOGY, May 1988, p. 816-820 Vol. 26, No. 5 0095-1137/88/050816-05$02.00/0 Copyright 1988, American Society for Microbiology Evaluation of MicroScan MIC Panels for Detection of
More informationChristiane Gaudreau* and Huguette Gilbert
Journal of Antimicrobial Chemotherapy (1997) 39, 707 712 JAC Comparison of disc diffusion and agar dilution methods for antibiotic susceptibility testing of Campylobacter jejuni subsp. jejuni and Campylobacter
More informationBarriers to Intravenous Penicillin Use for Treatment of Nonmeningitis
JCM Accepts, published online ahead of print on 7 July 2010 J. Clin. Microbiol. doi:10.1128/jcm.01012-10 Copyright 2010, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationMedicinal Chemistry 561P. 2 st hour Examination. May 6, 2013 NAME: KEY. Good Luck!
Medicinal Chemistry 561P 2 st hour Examination May 6, 2013 NAME: KEY Good Luck! 2 MDCH 561P Exam 2 May 6, 2013 Name: KEY Grade: Fill in your scantron with the best choice for the questions below: 1. Which
More informationAntimicrobial Susceptibility Testing: Advanced Course
Antimicrobial Susceptibility Testing: Advanced Course Cascade Reporting Cascade Reporting I. Selecting Antimicrobial Agents for Testing and Reporting Selection of the most appropriate antimicrobials to
More information2015 Antibiotic Susceptibility Report
Citrobacter freundii Enterobacter aerogenes Enterobacter cloacae Escherichia coli Haemophilus influenzenza Klebsiella oxytoca Klebsiella pneumoniae Proteus mirabilis Pseudomonas aeruginosa Serratia marcescens
More informationTitle: N-Acetylcysteine (NAC) Mediated Modulation of Bacterial Antibiotic
AAC Accepts, published online ahead of print on June 00 Antimicrob. Agents Chemother. doi:0./aac.0070-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationPILOT STUDY OF THE ANTIMICROBIAL SUSCEPTIBILITY OF SHIGELLA IN NEW ZEALAND IN 1996
PILOT STUDY OF THE ANTIMICROBIAL SUSCEPTIBILITY OF SHIGELLA IN NEW ZEALAND IN 996 November 996 by Maggie Brett Antibiotic Reference Laboratory ESR Communicable Disease Centre Porirua CONTENTS Page SUMMARY
More informationSurveillance for antimicrobial resistance in enteric bacteria in Australian pigs and chickens
Surveillance for antimicrobial resistance in enteric bacteria in Australian pigs and chickens Dr Pat Mitchell R & I Manager Production Stewardship APL CDC Conference, Melbourne June 2017 Dr Kylie Hewson
More informationAntibiotics & treatment of Acute Bcterial Sinusitis. Walid Reda Product Manager. Do your antimicrobial options meet your needs?
Antibiotics & treatment of Acute Bcterial Sinusitis Walid Reda Product Manager Do your antimicrobial options meet your needs? Antimicrobial Effects: What s involved? Effect in Humans: Serum concentration
More informationFlorida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC
Florida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC 11/20/2014 1 To describe carbapenem-resistant Enterobacteriaceae. To identify laboratory detection standards for carbapenem-resistant
More informationSTAPHYLOCOCCI: KEY AST CHALLENGES
Romney Humphries, PhD D(ABMM) Section Chief, UCLA Clinical Microbiology Los Angeles CA rhumphries@mednet.ucla.edu STAPHYLOCOCCI: KEY AST CHALLENGES THE CHALLENGES detection of penicillin resistance detection
More informationDefining Extended Spectrum b-lactamases: Implications of Minimum Inhibitory Concentration- Based Screening Versus Clavulanate Confirmation Testing
Infect Dis Ther (2015) 4:513 518 DOI 10.1007/s40121-015-0094-6 BRIEF REPORT Defining Extended Spectrum b-lactamases: Implications of Minimum Inhibitory Concentration- Based Screening Versus Clavulanate
More informationShort Report. R Boot. Keywords: Bacteria, antimicrobial susceptibility testing, quality, diagnostic laboratories, proficiency testing
Short Report Frequent major errors in antimicrobial susceptibility testing of bacterial strains distributed under the Deutsches Krebsforschungszentrum Quality Assurance Program R Boot Former Section of
More informationOriginal Article. Suthan Srisangkaew, M.D. Malai Vorachit, D.Sc.
Original Article Vol. 21 No.1 The optimum agent for ESBL screening and confirmatory tests:- Srisangkaew S & Vorachit M. 1 The Optimum Agent for Screening and Confirmatory Tests for Extended-Spectrum Beta-Lactamases
More information2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process High Priority
Quality ID #65 (NQF 0069): Appropriate Treatment for Children with Upper Respiratory Infection (URI) National Quality Strategy Domain: Efficiency and Cost Reduction Meaningful Measure Area: Appropriate
More informationTowards Rational International Antibiotic Breakpoints: Actions from the European Committee on Antimicrobial Susceptibility Testing (EUCAST)
Towards Rational International Antibiotic Breakpoints: Actions from the European Committee on Antimicrobial Susceptibility Testing (EUCAST) A report to ISC presented by Paul M. Tulkens representative of
More informationCAP Laboratory Improvement Programs. Performance Accuracy of Antibacterial and Antifungal Susceptibility Test Methods
CAP Laboratory Improvement Programs Performance Accuracy of Antibacterial and Antifungal usceptibility Test Methods Report From the College of American Pathologists Microbiology urveys Program (001 003)
More informationagainst Clinical Isolates of Gram-Positive Bacteria
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 993, p. 366-370 Vol. 37, No. 0066-0/93/00366-05$0.00/0 Copyright 993, American Society for Microbiology In Vitro Activity of CP-99,9, a New Fluoroquinolone,
More information